Literature DB >> 25637052

Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.

Lars P Jordheim1, Vincent Ribrag2, Hervé Ghesquieres3, Sophie Pallardy4, Richard Delarue5, Hervé Tilly6, Corinne Haioun7, Fabrice Jardin8, Delphine Demangel9, Gilles A Salles10, Charles Dumontet11.   

Abstract

Entities:  

Keywords:  ABCB1; CBR1; R-CHOP; SNP; non-Hodgkin lymphoma; toxicity

Mesh：

Substances：

Year:  2015        PMID： 25637052      PMCID： PMC4420233          DOI： 10.3324/haematol.2014.120113

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.

Authors:  Onkar S Bains; András Szeitz; Joanna M Lubieniecka; Gina E Cragg; Thomas A Grigliatti; K Wayne Riggs; Ronald E Reid
Journal:  J Pharmacol Exp Ther       Date:  2013-08-30       Impact factor: 4.030

Review 2.  Pharmacogenetics of genes across the doxorubicin pathway.

Authors:  David Jamieson; Alan V Boddy
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10       Impact factor: 4.481

3.  Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.

Authors:  Donato Gemmati; Alessia Ongaro; Silvia Tognazzo; Linda Catozzi; Federica Federici; Endri Mauro; Matteo Della Porta; Diana Campioni; Antonella Bardi; Giuseppe Gilli; Agnese Pellati; Angelo Caruso; Gian L Scapoli; Monica De Mattei
Journal:  Haematologica       Date:  2007-04       Impact factor: 9.941

4.  Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.

Authors:  Vincent Ribrag; Serge Koscielny; Olivier Casasnovas; Cecile Cazeneuve; Pauline Brice; Franck Morschhauser; Jean Gabarre; Aspasia Stamatoullas; Gilbert Lenoir; Gilles Salles
Journal:  Blood       Date:  2008-09-03       Impact factor: 22.113

5.  Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).

Authors:  Vanessa Gonzalez-Covarrubias; James L Kalabus; Javier G Blanco
Journal:  Pharm Res       Date:  2008-05-01       Impact factor: 4.200

6.  Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.

Authors:  Onkar S Bains; Morgan J Karkling; Thomas A Grigliatti; Ronald E Reid; K Wayne Riggs
Journal:  Drug Metab Dispos       Date:  2009-02-09       Impact factor: 3.922

7.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

Authors:  Herve Tilly; Eric Lepage; Bertrand Coiffier; Michel Blanc; Raoul Herbrecht; Andre Bosly; Michel Attal; Georges Fillet; Catherine Guettier; Thierry Jo Molina; Christian Gisselbrecht; Felix Reyes
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

8.  Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.

Authors:  Savitha Varatharajan; Ajay Abraham; Wei Zhang; R V Shaji; Rayaz Ahmed; Aby Abraham; Biju George; Alok Srivastava; Mammen Chandy; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Eur J Clin Pharmacol       Date:  2012-05-05       Impact factor: 2.953

Review 9.  P-glycoprotein Inhibition for Optimal Drug Delivery.

Authors:  Md Lutful Amin
Journal:  Drug Target Insights       Date:  2013-08-19

10.  MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024.

Authors:  James L Kalabus; Qiuying Cheng; Javier G Blanco
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240
View more
  5 in total

Review 1.  Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.

Authors:  Tarek Magdy; Paul W Burridge
Journal:  Pharmacogenomics       Date:  2021-01-15       Impact factor: 2.533

2.  ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.

Authors:  Duo Liu; Nan Wu; Haiming Sun; Mei Dong; Tianzhu Guo; Peng Chi; Guofu Li; Donglin Sun; Yan Jin
Journal:  Oncotarget       Date:  2017-04-06

3.  Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.

Authors:  Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Dorota Butkiewicz; Ewa Grzybowska
Journal:  Oncotarget       Date:  2018-01-10

Review 4.  Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?

Authors:  Beata Franczyk; Jacek Rysz; Jarosław Miłoński; Tomasz Konecki; Magdalena Rysz-Górzyńska; Anna Gluba-Brzózka
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-13

Review 5.  Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).

Authors:  Pablo Zubiaur; Dora Koller; Miriam Saiz-Rodríguez; Marcos Navares-Gómez; Francisco Abad-Santos
Journal:  Clin Transl Sci       Date:  2020-09-16       Impact factor: 4.689
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.